



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09 126,945	07 31 1998	TOWIA ARON LIBERMANN	1488.1090000	9528

7590

07 30 2002

STERNE KESSLER GOLDSTEIN AND FOX
SUITE 600
1100 NEW YORK AVENUE N W
WASHINGTON, DC 200053934

EXAMINER

PRIEBE, SCOTT DAVID

ART UNIT	PAPER NUMBER
----------	--------------

1632

DATE MAILED: 07 30 2002

41

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.
09/126,945

Applicant(s)
Libermann et al.

Examiner
Scott D. Priebe, Ph.D.

Art Unit
1632



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED Jul 3, 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

Therefore, further action by the applicant is required to avoid the abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

THE PERIOD FOR REPLY [check only a) or b)]

- a) ☐ The period for reply expires _____ months from the mailing date of the final rejection.
- b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. ☒ A Notice of Appeal was filed on Apr 23, 2002. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. ☒ The proposed amendment(s) will not be entered because:
- (a) ☒ they raise new issues that would require further consideration and/or search (see NOTE below);
- (b) ☒ they raise the issue of new matter (see NOTE below);
- (c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
- (d) ☒ they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: Proposed amendment of claims 173, 196, 199, 207, 210, 236, 239, 247, 250, 257, 260, 273, 276
causes new matter in claims 174, 197, 200, 208, 211, 237, 240, 248, 251, 258, 261, 274, 277.

3. ☐ Applicant's reply has overcome the following rejection(s):

4. ☒ Newly proposed or amended claim(s) see following pages would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

5. ☒ The a) ☐ affidavit, b) ☐ exhibit, or c) ☒ request for reconsideration has been considered but does NOT place the application in condition for allowance because:
see following pages.

6. ☐ The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.

7. ☒ For purposes of Appeal, the proposed amendment(s) a) ☒ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: 203-206, 209, 212-228, 243-246, 249, 252-256, 259, and 280-287

Claim(s) objected to: 159, 160, 162, 163, 165, 166, 168, 169, 183, 186, 189, 192, 230, and 232

Claim(s) rejected: 157, 158, 161, 167, 170-181, 184, 187, 190, 193-202, 207, 208, 210, 211, 236, 237, 239, 240,

Claim(s) withdrawn from consideration: 247, 248, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000

8. ☐ The proposed drawing correction filed on _____ is a) ☐ approved or b) ☐ disapproved by the Examiner.

9. ☐ Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____

10. ☐ Other: _____

SCOTT D. PRIEBE, PH.D.
PRIMARY EXAMINER
ART UNIT 1632

Art Unit: 1632

Advisory Action

Item 2.d. (cont.):

The proposed amendment to claims 173, etc. does not require any particular association between the heterologous sequence and the "nucleic acid". However, the specification describes embodiments of operable association of the transcription/translation elements to a nucleic acid encoding all or part of SEQ ID NO: 2. Thus, the amendment of claims 173, etc. results in an increase in breadth in claims 174, etc. not supported by the specification, as indicated before in the Advisory Action of 5/6/02. As indicated in the final rejection, the limitations of claim 174 and claims 248 and 251 are out of context with respect claim 157 and claim 243, respectively. Claims 174, 248, and 251 should be cancelled, as was proposed for claim 177. This new matter issue would be obviated for claims 197, 200, 208, 211, 237, 240, 258, 261, 274 and 277 by amending these claims to include the limitation that the heterologous sequence "selected" is operably associated with the "nucleic acid" encoding part or all of SEQ ID NO: 2 AND amending claims 196, 199, 207, 210, 236, 239, 257, 260, 273, and 276 as proposed.

Item 4:

Claims 157, 159-160, 162-163, 165-166, 168-173, 175-176, 179, 207, 210, 230, 232, 247, 250, 257, 260, 264-273, 275, 276, 278.

Also, claims 208, 211, 248, 251, 258, 261, 274 and 277 amended as indicated above would be allowable.

Art Unit: 1632

The proposed amendment to the specification would overcome the objection to the specification.

Item 5:

Applicant argues that the specification (page 16) teaches that polypeptides that vary from SEQ ID NO: 2 by insertions, deletions, and substitutions anywhere in SEQ ID NO: 2 can be used to make antibodies. Whereas, the Office contends that the specification describes and enables only using fragments of SEQ ID NO: 2. Pages 15-16 of the specification describes variants of PDEF and how they may be expected to retain a generic biological activity, e.g. transcription factor activity. When discussing the binding of a variant to an antibody specifically (page 16, lines 4-11), the *only* types of variants discussed are those which are fragments of PDEF having deletions of amino acids specifically from the N- or C- terminus. No other types of variant are mentioned in this context. While other types of variation are contemplated with respect to biological activities in general, only N- and C- terminal deletion is discussed in the context of antibody binding or immunogenic activity. Applicant's attempts to deconstruct the specification are not convincing. Applicant has yet to provide any evidence that it was routine for one of skill in the art to intentionally alter a protein sequence by random substitution, insertion, and deletion, and then use that altered protein to produce antibodies for binding to the original protein, and there is no guidance in the specification for doing so. The previous Office actions have already

Application/Control Number: 09/126,945

Page 4

Art Unit: 1632

indicated that the specification enabled the use of fragments of SEQ ID NO: 2, which is the subject of page 16, lines 4-11.

Scott D. Pribe
SCOTT D. PRIEBE, PH.D
PRIMARY EXAMINER